Jeremy Nighohossian is a senior fellow and economist at the Competitive Enterprise Institute, focusing on health care policy. His expertise is in healthcare antitrust and regulation including Certificate of Need regulations and competition and federal and state reimbursement policies. Jeremy writes on how government regulation and dominance of the healthcare sector stifle innovation, reduce quality, and raise costs.
Jeremy holds a Ph.D. in economics from Texas A&M University and a B.S. in Chemical Engineering from the University of Illinois. Before joining CEI, he worked at the Center for Healthcare Economics and Policy at FTI Consulting where he specialized in anti-trust and disputes in healthcare working on several projects with Compass Lexecon. While at FTI, Dr. Nighohossian built a policy analysis practice where he conducted analyses of state and national healthcare policies. Jeremy’s expertise has taken him around the world, testifying to the South Africa Competition Commission on hospital prices and how they relate to supply and he helped design a value-based payment system in the UK.
Authored by Jeremy Nighohossian
News
Report: Pharmaceutical tariffs will upend prices, supply
A new CEI report takes a close look at the complex, worldwide pharmaceutical supply chain to anticipate how forthcoming Trump tariffs might increase prices and…
Trump’s views on Tylenol shouldn’t supersede doctor advice
President Trump railed against Tylenol (acetaminophen) in a press conference this week, imploring, in particular, pregnant women and babies to not take (or be administered)…
US/EU trade agreement underwhelms: CEI analysis
As a follow up to last month’s US/EU trade agreement that set 15 percent blanket tariffs on EU exports to the US (among other provisions), today…
Blog
Obamacare’s subsidy cliff: How many enrollees are actually affected?
Democrats in Congress have put Obamacare front and center in their opposition to the Republicans’ temporary budget. One provision of the American Rescue Plan…
The TrumpRx medicine will prove worse than the disease
On September 30, President Trump, standing alongside the CEO of Pfizer, announced a multifaceted deal wherein Pfizer would inoculate itself from new regulations and…
The problem with Obamacare is Obamacare
This year, the COVID-induced expansion of the Affordable Care Act (ACA) will expire. Extending the expanded subsidies has become a point of contention between Republicans…
Op-Eds/Articles
National Review
RFK Jr.’s Cherry-Picked Science
One of Robert F. Kennedy Jr.’s promises as secretary of health and human services was to bring gold-standard science to our public…
DC Journal
Point: Medicaid Work Requirements Are a Common-Sense Reform
Medicaid is the government program that is supposed to help the poor afford health care. Its cost to taxpayers has skyrocketed in the last few…
DC Journal
What the Media Gets Wrong About Medicaid ‘Cuts’
Headlines assert that the reforms Republicans recently passed amount to a trillion-dollar cut to Medicaid. The New York Times calls this the most significant cut to federal…
Studies
I, Pharmaceutical
The global pharmaceutical industry is complex. This is true not only in the number of countries involved but the range of products, the sets of…
Citations
InsideHealthPolicy
Shutdown Stalled Deregulatory Action At HHS, In Congress
“Jeremy Nighohossian, a health policy expert and economist at regulatory reform organization the Competitive Enterprise Institute (CEI), told Inside Health Policy in a statement that…
The Washington Examiner
Capping drug prices will cripple innovation and harm public health
The Washington Examiner cited CEI’s expert on life-saving drugs and technology The Competitive Enterprise Institute was similarly scathing. “As with many industries, the United States…
Politico
Playbook PM: Setting the table for Switzerland
TRANSITION — Jeremy Nighohossian is now a senior fellow and economist at the Competitive Enterprise Institute focusing on health care policy. He previously worked at FTI…
Podcast Episodes
Obamacare Problems with Jeremy Nighohossian
This week we talk about the unintended consequences of the Sarbanes-Oxley Act of 2002, decarbonization of economic growth, and resources for reporting government corruption at...